New microbiome insights could help boost immunotherapy for a range of rare cancers

March 1, 2024 9:00 am

Clearity’s Perspective: Previous research in different types of cancer has suggested that there is a relationship between a cancer patient’s gut microbiota (microorganisms that live in the digestive tract) composition and the response to immune checkpoint inhibitor therapy; however,

Read more

Cancer Prevention Strategies Linked to Mortality Reduction in BRCA Carriers

February 29, 2024 9:00 am

By Mike Basset

Risk management strategies including bilateral salpingo-oophorectomy (BSO) for ovarian cancer and MRI surveillance for breast cancer were associated with a significant reduction in mortality for women with BRCA1/2 sequence variations, according to results from two cohort studies … Read more

Study Shows Disparities in Psychosocial Outcomes Among Women With Ovarian Cancer in Rural vs Urban Areas

February 23, 2024 9:00 am

Clearity’s Perspective: Clearity offers emotional support to people with ovarian cancer and their caregivers through our Steps Through OC program. If you would like personal one-to-one assistance with the stress and challenges associated with an ovarian cancer diagnosis, our team Read more

Ursula Matulonis, MD, on Concordance of CA-125 and Radiographic Progression in Ovarian Cancer

February 21, 2024 9:00 am

By Mark Fuerst

About half of patients with platinum-sensitive relapsed ovarian cancer (PSROC) on maintenance poly (ADP-ribose) polymerase inhibitor (PARPi) therapy who showed RECIST progression did not have cancer antigen-125 (CA-125) progression, challenging current guidelines, according to a new study.… Read more

This Could Be a Strong Weapon for Cancer Pain (or Any Pain)

February 21, 2024 9:00 am

By Courtney Southwick

Exercising for upwards of 30 minutes most days may help relieve pain in patients who’ve been diagnosed with cancer, according to a study of exercise and pain outcomes from more than 60,000 people, including 10,000 with a … Read more

Patients and Doctors Push Back Against the Harsh Side Effects of Cancer Drugs

— “If the patients are not taking the drug, then it’s not going to work”

February 6, 2024 10:30 am

By Associated Press.

For cancer patients, the harsh side effects of powerful drugs have long been the trade-off for living longer. Now, patients and doctors are questioning whether all that suffering is necessary.

They’ve ignited a movement to radically change … Read more

Priority Review Granted for Trastuzumab Deruxtecan; Would Be First Tumor-Agnostic ADC

A tumor-agnostic approval would be a significant development in the advance of antibody-drug conjugates (ADCs), which are designed to deliver a potent, cancer-fighting payload into a tumor while sparing nearby tissues.

January 30, 2024 9:00 am

Clearity’s Perspective: Most drugs are tested and approved to treat cancers based on where in the body the cancer started and the type of tissue from which it developed. Enhertu (Trastuzumab Deruxtecan, T-Dxd), a HER2-targeted antibody drug conjugate (ADC), already Read more

Lack of resource ‘equality’ means research of the deadliest cancers is often underfunded

January 26, 2024 9:00 am

By Josh Friedman

Key takeaways:

  • Breast cancer received 25% of cancer funding from 2015 to 2018.
  • Cancers with high mortality rates, such as colorectal and pancreatic cancer, are underfunded.

Cancer research and advocacy funding disproportionately skewed toward certain subtypes, leaving … Read more

Diagnosing the “Silent Killer”: AI Tackles Early Stage Ovarian Cancer

January 26, 2024 9:00 am

By Fay Lin, PhD

A major bottleneck in early detection is the molecular heterogeneity between ovarian cancer (OC) patients, which limits the likelihood of identifying individual biomarkers that are shared among patients. In a new study “A personalized probabilistic Read more

Real-World Data Confirm the Incidence of ADC-Related Ocular Toxicities in Ovarian Cancer

January 26, 2024 9:00 am

By Ashling Wahner

Although the antibody-drug conjugate (ADC) mirvetuximab soravtansine-gynx (Elahere) is associated with a high rate of ocular toxicity in patients with folate receptor α (FRα)-positive, platinum-resistant ovarian cancer, the real-world incidence of this adverse effect (AE) in this … Read more

NCCN Guidelines Update Adds Mirvetuximab Soravtansine Plus Bevacizumab for FRα-Expressing, Platinum-Sensitive Ovarian Cancer

January 19, 2024 9:00 am

Clearity’s Perspective: In the January 17, 2024 update to the National Comprehensive Cancer Network (NCCN) guidelines for ovarian cancer, several new therapies have been added to the list of acceptable regimens for recurrent platinum-resistant ovarian cancer. For example, trastuzumab deruxtecan Read more

Life Experience of Survivors of Gynecologic Cancers: A Survey Conducted in Italy

January 11, 2024 9:00 am

Clearity offers emotional support to people diagnosed with ovarian cancer and their caregivers through our Steps Through OC program. If you would like personalized, one-to-one assistance with navigating the impact of an ovarian cancer diagnosis, our team of OC Counselors Read more

Gynecologic cancer clinical trial enrollment lower for certain underrepresented groups

December 29, 2023 9:00 am

By Erin T. Welsh, MA

Key takeaways:

  • Clinical trial enrollment was lower for Asian, Black and Hispanic women vs. white women.
  • Asian and Hispanic women were underrepresented in endometrial, cervical and ovarian cancer trials.

Asian, Black and Hispanic women with … Read more

Trial Analyzing MEK Inhibitor Combo for Ovarian Cancer Subset Begins

December 21, 2023 9:00 am

By Ashley Chan

A treatment combination of avutometinib and defactinib is being evaluated in a new phase 3 trial for patients with low-grade serous ovarian cancer.

A phase 3 trial analyzing the treatment combination of avutometinib and defactinib compared with … Read more

Psilocybin May Help Ease Depression in Cancer Patients

In small trial, half had early remission of depressive symptoms after psilocybin-assisted therapy

December 18, 2023 9:00 am

By Diana Swift

Psilocybin-assisted therapy in a group setting was safe and appeared effective in patients with cancer and depression, according to a small, phase II, open‐label trial.

After one dose of psilocybin among 30 patients, depression severity scores dropped … Read more

Virtual Mind–Body Fitness Classes Show Unexpected Benefit in People with Cancer

December 15, 2023 9:00 am

By Edward Winstead

For people being treated for cancer, participating in virtual mind–body fitness classes may have important benefits, such as reducing the risk of being hospitalized for treatment-related problems, according to results from a clinical trial.

In the trial, … Read more

What Comes after NCI-MATCH? NCI’s New Precision Medicine Cancer Trials

December 6, 2023 9:00 am

By James H. Doroshow, M.D.

More than 8 years ago, NCI launched NCI-MATCH, a first-of-its-kind precision medicine cancer clinical trial. NCI-MATCH tested different targeted therapies in people with cancer whose tumors had specific genetic changes. This year, three second-generation precision

Read more

Ovarian Cancer Detected Early With DNA From Pap Smear in Proof-of-Principle Study

December 6, 2023 9:00 am

By Andrea Anderson

NEW YORK – An Italian team led by investigators at Humanitas University has come up with a test for detecting early-stage high-grade serous ovarian cancer (HGSOC) that relies on DNA sequencing of cervical smear samples collected during … Read more

From diagnosis through survivorship: Mindfulness can help people cope with cancer

Research has shown mindful meditation can reduce stress, relieve pain.

November 29, 2023 9:00 am

Clearity offers psychosocial support to caregivers through our Steps Through OC program. If you would like personal one-to-one assistance with the stress and challenges associated with caring for a loved one with an ovarian cancer diagnosis, our team of OC Read more

PC14586 Targets Previously “Undruggable” p53 in Treatment of Solid Tumors

Despite previous unsuccessful attempts to target p53, investigators have continued to try to develop novel therapeutics directed at the tumor suppressor gene with the goal of restoring p53 wild-type activity.

November 27, 2023 9:00 am

By Kyle Doherty

Despite previous unsuccessful attempts to target p53, investigators have continued to try to develop novel therapeutics directed at the tumor suppressor gene with the goal of restoring p53 wild-type activity. With the initiation of the phase … Read more